JP2020501612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501612A5 JP2020501612A5 JP2019554474A JP2019554474A JP2020501612A5 JP 2020501612 A5 JP2020501612 A5 JP 2020501612A5 JP 2019554474 A JP2019554474 A JP 2019554474A JP 2019554474 A JP2019554474 A JP 2019554474A JP 2020501612 A5 JP2020501612 A5 JP 2020501612A5
- Authority
- JP
- Japan
- Prior art keywords
- transposase
- seq
- cells
- stem cells
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008579 Transposases Human genes 0.000 claims description 152
- 108010020764 Transposases Proteins 0.000 claims description 152
- 150000001413 amino acids Chemical group 0.000 claims description 66
- 230000004927 fusion Effects 0.000 claims description 62
- 235000001014 amino acid Nutrition 0.000 claims description 57
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 49
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 210000000130 stem cell Anatomy 0.000 claims description 11
- 230000007935 neutral effect Effects 0.000 claims description 10
- 108700019146 Transgenes Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000009870 specific binding Effects 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 108091008875 B cell receptors Proteins 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 230000017105 transposition Effects 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 102000001749 Immunologic Receptors Human genes 0.000 claims description 3
- 108010054738 Immunologic Receptors Proteins 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 102100029812 Protein S100-A12 Human genes 0.000 claims description 3
- 101710110949 Protein S100-A12 Proteins 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 238000006384 oligomerization reaction Methods 0.000 claims description 3
- 210000004986 primary T-cell Anatomy 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 102220036871 rs587780095 Human genes 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004504 adult stem cell Anatomy 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 210000002514 epidermal stem cell Anatomy 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000004216 mammary stem cell Anatomy 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 238000000520 microinjection Methods 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 210000001938 protoplast Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004990 primary immune cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435522P | 2016-12-16 | 2016-12-16 | |
| US62/435,522 | 2016-12-16 | ||
| PCT/US2017/066829 WO2018112415A1 (en) | 2016-12-16 | 2017-12-15 | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501612A JP2020501612A (ja) | 2020-01-23 |
| JP2020501612A5 true JP2020501612A5 (enExample) | 2021-02-04 |
| JP7275043B2 JP7275043B2 (ja) | 2023-05-17 |
Family
ID=62559537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554474A Active JP7275043B2 (ja) | 2016-12-16 | 2017-12-15 | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11111483B2 (enExample) |
| EP (2) | EP3555273B1 (enExample) |
| JP (1) | JP7275043B2 (enExample) |
| KR (1) | KR102523318B1 (enExample) |
| CN (1) | CN110730821B (enExample) |
| AU (1) | AU2017378482B2 (enExample) |
| CA (1) | CA3047313A1 (enExample) |
| EA (1) | EA201991431A1 (enExample) |
| IL (1) | IL267334B2 (enExample) |
| WO (1) | WO2018112415A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| CA3104288A1 (en) * | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| EP4146798A4 (en) * | 2020-05-04 | 2025-02-12 | Saliogen Therapeutics, Inc. | TRANSPOSITION-BASED THERAPIES |
| EP4161950A4 (en) * | 2020-06-05 | 2024-06-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family member spin transposon-mediated gene transfer and associated compositions, systems, and methods |
| EP4165180A4 (en) | 2020-06-16 | 2024-10-23 | Bio-Techne Corporation | MODIFIED MAD7-DIRECTED ENDONUCLEASE |
| CN111607661B (zh) * | 2020-06-29 | 2022-06-14 | 北部湾大学 | 基于油茶转录组hAT转座子的分子标记引物组及其应用 |
| CN111607662B (zh) * | 2020-06-30 | 2022-06-10 | 北部湾大学 | 基于白骨壤转录组hAT转座子的分子标记引物组及其应用 |
| US20240327861A1 (en) * | 2021-07-09 | 2024-10-03 | Neogentc Corp. | Transposon system and uses thereof |
| WO2023004366A1 (en) | 2021-07-21 | 2023-01-26 | Aspen Neuroscience, Inc. | Transposon-based modulation of gba1 and related compositions and uses thereof |
| WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025054409A1 (en) * | 2023-09-07 | 2025-03-13 | Bio-Techne Corporation | Mutant tcbuster transposase with improved solubility |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025156492A1 (zh) * | 2024-01-23 | 2025-07-31 | 星尘股份有限公司 | 转座酶及其用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067644B2 (en) | 2000-12-05 | 2006-06-27 | Wisconsin Alumni Research Foundation | Double transposition methods for manipulating nucleic acids |
| US7064246B2 (en) | 2001-05-01 | 2006-06-20 | Macrae Amy F | Use of transposable elements for altering gene expression |
| US7262056B2 (en) | 2001-11-08 | 2007-08-28 | Mirus Bio Corporation | Enhancing intermolecular integration of nucleic acids using integrator complexes |
| AU2002360986A1 (en) | 2001-12-20 | 2003-07-09 | Sungene Gmbh And Co. Kgaa | Methods for the transformation of vegetal plastids |
| DK1594973T3 (da) | 2003-02-10 | 2012-02-13 | Max Delbrueck Centrum | Transposonbaseret målretningssystem |
| US20080008687A1 (en) | 2003-02-10 | 2008-01-10 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | Transposon-Based Targeting System |
| US7985739B2 (en) * | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
| GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
| US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US20060252140A1 (en) * | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| EP2392657B1 (en) | 2005-07-05 | 2013-09-25 | The Chemo-Sero-Therapeutic Research Institute | Modified transposon vector and its use |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| US8524979B2 (en) | 2008-04-14 | 2013-09-03 | National Taiwan University | Termination of transgene expression via transposon-mediated break |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| US8399643B2 (en) | 2009-02-26 | 2013-03-19 | Transposagen Biopharmaceuticals, Inc. | Nucleic acids encoding hyperactive PiggyBac transposases |
| ES2697535T3 (es) | 2009-06-11 | 2019-01-24 | Inter Univ Research Institute Corporation Research Organization Of Information And Systems | Procedimiento para la producción de proteína |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130017978A1 (en) | 2011-07-11 | 2013-01-17 | Finnzymes Oy | Methods and transposon nucleic acids for generating a dna library |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| US9738874B2 (en) * | 2011-12-16 | 2017-08-22 | Novozymes Inc. | Polypeptides having laccase activity and polynucleotides encoding same |
| DK2825190T3 (en) | 2012-03-15 | 2017-02-27 | Cellectis | REPEAT VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES |
| CN102690354B (zh) * | 2012-05-14 | 2015-03-25 | 安源生物科技(上海)有限公司 | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统 |
| PT2692865E (pt) | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
| FI3536797T3 (fi) | 2013-02-01 | 2023-03-23 | Selexis Sa | Siirtogeenin tehostettu ilmentäminen ja prosessointi |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| NZ759969A (en) * | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| AU2015234242B2 (en) | 2014-03-21 | 2020-09-24 | Children's Medical Research Institute | Stable gene transfer to proliferating cells |
| CN103981204B (zh) | 2014-03-24 | 2016-05-04 | 上海海洋大学 | 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法 |
| DK3129487T3 (da) | 2014-04-09 | 2020-11-30 | Dna Twopointo Inc | Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression |
| US20170107541A1 (en) | 2014-06-17 | 2017-04-20 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| JP2017534295A (ja) | 2014-09-29 | 2017-11-24 | ザ ジャクソン ラボラトリー | エレクトロポレーションによる遺伝子改変哺乳動物の高効率ハイスループット生成 |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| JP2018513681A (ja) | 2015-03-31 | 2018-05-31 | エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. | 細胞または生物のゲノムへのＤＮＡ配列の標的化組み込みのためのＣａｓ９レトロウイルスインテグラーゼおよびＣａｓ９レコンビナーゼ系 |
| CN107980059B (zh) | 2015-04-13 | 2022-11-11 | 美克斯细胞有限公司 | 用于修饰基因组dna的方法和组合物 |
| WO2016191618A1 (en) | 2015-05-27 | 2016-12-01 | Jianbiao Zheng | Methods of inserting molecular barcodes |
| US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| WO2017046259A1 (en) | 2015-09-16 | 2017-03-23 | Ethris Gmbh | Improved transposon system for gene delivery |
| ES3063691T3 (en) | 2015-09-22 | 2026-04-20 | Univ Wuerzburg J Maximilians | A method for high level and stable gene transfer in lymphocytes |
| CN105154473B (zh) | 2015-09-30 | 2019-03-01 | 上海细胞治疗研究院 | 一种高效安全的转座子整合系统及其用途 |
| EP4289944A3 (en) | 2015-10-08 | 2024-03-13 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
| KR102249982B1 (ko) * | 2015-12-14 | 2021-05-11 | 게놈프론티어 테라퓨틱스 인코포레이티드 | 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 |
| WO2017123758A1 (en) | 2016-01-12 | 2017-07-20 | Seqwell, Inc. | Compositions and methods for sequencing nucleic acids |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| CN109312361A (zh) | 2016-02-26 | 2019-02-05 | 波赛伊达治疗学股份有限公司 | 转座子系统及应用方法 |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| KR20190006952A (ko) | 2016-03-31 | 2019-01-21 | 라이언 티씨알 피티이. 리미티드 | 외인성 바이러스-특이적 t 세포 수용체 (tcr)를 발현하는 비-활성화된 t 세포 |
| EP3452082A1 (en) | 2016-05-04 | 2019-03-13 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| CN107523547A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抑制性抗体的car‑t细胞及其用途 |
| CN107523549A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达激活型抗体的car‑t细胞及其用途 |
| CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| CN107523548A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的t细胞及其用途 |
| KR20190031306A (ko) | 2016-07-21 | 2019-03-25 | 맥스시티 인코포레이티드 | 게놈 dna를 변경하기 위한 방법 및 조성물 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018042776A1 (ja) | 2016-08-30 | 2018-03-08 | 国立大学法人九州大学 | Ｄｎａ結合タンパク質の結合領域の近傍に所望のｄｎａ断片を挿入する方法 |
| WO2018057779A1 (en) | 2016-09-23 | 2018-03-29 | Jianbiao Zheng | Compositions of synthetic transposons and methods of use thereof |
| CA3036926C (en) | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| US11793833B2 (en) | 2016-12-02 | 2023-10-24 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| EP3568474A1 (en) | 2017-01-10 | 2019-11-20 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| WO2018140644A1 (en) | 2017-01-25 | 2018-08-02 | Musc Foundation For Research Development | Modified t cells and uses thereof |
-
2017
- 2017-12-15 JP JP2019554474A patent/JP7275043B2/ja active Active
- 2017-12-15 EA EA201991431A patent/EA201991431A1/ru unknown
- 2017-12-15 US US15/844,363 patent/US11111483B2/en active Active
- 2017-12-15 WO PCT/US2017/066829 patent/WO2018112415A1/en not_active Ceased
- 2017-12-15 EP EP17880424.1A patent/EP3555273B1/en active Active
- 2017-12-15 CN CN201780086768.7A patent/CN110730821B/zh active Active
- 2017-12-15 AU AU2017378482A patent/AU2017378482B2/en active Active
- 2017-12-15 EP EP24170568.0A patent/EP4421167A3/en active Pending
- 2017-12-15 CA CA3047313A patent/CA3047313A1/en active Pending
- 2017-12-15 KR KR1020197020507A patent/KR102523318B1/ko active Active
- 2017-12-15 IL IL267334A patent/IL267334B2/en unknown
-
2018
- 2018-04-20 US US15/958,834 patent/US20180245055A1/en not_active Abandoned
- 2018-06-11 US US16/005,270 patent/US10227574B2/en active Active
-
2020
- 2020-02-12 US US16/789,188 patent/US11162084B2/en active Active
-
2021
- 2021-10-22 US US17/508,522 patent/US12037611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501612A5 (enExample) | ||
| US20250320491A1 (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| US20230159927A1 (en) | Chromatin remodelers to enhance targeted gene activation | |
| JP7275043B2 (ja) | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 | |
| KR20240130158A (ko) | 효율적인 생체내 전달을 위한 조성물 및 방법 | |
| JP7733865B2 (ja) | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 | |
| CN113302292B (zh) | 遗传修饰细胞的减少和最少的操作制造 | |
| JP2021527427A5 (enExample) | ||
| US12097220B2 (en) | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods | |
| EP4125350A1 (en) | Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1) | |
| CN114945666A (zh) | 用于rna分子高效重组的组合物和方法 | |
| WO2020160489A1 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| US12419915B2 (en) | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof | |
| CN121227639A (zh) | 具有增强肿瘤靶向浸润能力的间充质干细胞及其应用 | |
| CN121127501A (zh) | 锌指蛋白、锌指核酸酶、载体和应用它们的基因组编辑方法 | |
| WO2025223340A1 (zh) | 一种鉴定靶标的方法及其应用 | |
| CN120519490A (zh) | 一种新型杂交dna载体及其应用 | |
| CA3218195A1 (en) | Abca4 genome editing | |
| HK40069063B (zh) | 用於治疗地中海贫血或镰状细胞病的方法和组合物 |